You are here: Industry Insights > AstraZeneca

News List

Pharma stocks fall after new drug price probe in US pharmaphorum
January 16, 2019
US politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their shares to drop suddenly.
AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backing fiercepharma
January 08, 2019
Back in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is in the fast lane thanks to an expanded recommendation.
AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure fiercepharma
January 08, 2019
With key commercial cog Mark Mallon bound for Ironwood Pharmaceuticals' CEO spot, AstraZeneca is shaking up its corporate structure and revamping top management.
Ironwood swipes AZ commercial hotshot Mark Mallon to fill its CEO chair fiercepharma
January 08, 2019
Hitting the road this time is Mark Mallon, AstraZeneca’s EVP of global product and portfolio strategy, and he’ll be taking up the CEO baton at newly revamped Ironwood.
AstraZeneca Announces Organizational Changes americanpharmaceuticalreview
January 08, 2019
AstraZeneca has announced organizational changes that include the arrival of oncology scientist, José Baselga.Other changes include the creation of .....
NICE broadens approval for AstraZeneca’s severe asthma drug pharmaphorum
January 07, 2019
AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for......
AstraZeneca’s tremelimumab fails another phase 3 cancer trial fiercebiotech
December 28, 2018
AstraZeneca’s tremelimumab has come up short in another phase 3 trial. Having failed to improve outcomes in metastatic non-small cell lung cancer (NSCLC).....
Feds abandon 11 'white-coat' kickback probes, questioning whistleblower motives instead fiercepharma
December 25, 2018
After digging into almost a dozen whistleblower complaints alleging pharma companies ran kickback schemes with nurse educators as the "payment"—so-called white-coat marketing—the government is backing out.
AstraZeneca, Merck's Lynparza plows ahead in ovarian cancer with $1B-plus approval, phase 3 data fiercepharma
December 24, 2018
The year may be winding down, but AstraZeneca and Merck’s Lynparza sure isn’t. It picked up a blockbuster new approval late Wednesday and followed up the act by posting positive phase 3 data Thursday morning.
AVEO Oncology Announces Clinical Collaboration with AstraZeneca americanpharmaceuticalreview
December 24, 2018
AVEO Oncology has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's Imfinzi (durvalumab).....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page